She knows more information about her cancer.
Before considering chemotherapy.
Although about 80% of Stage II colon cancer patients are cured with surgery alone, approximately 20% of these patients will recur following surgery. Even with currently available tools, physicians face the challenge of determining which patients are at higher risk of recurrence and may be candidates for adjuvant chemotherapy before making treatment decisions. Precision's GeneFxSM
Colon has been validated to assess a patient's risk of recurrence within 5 years.
What is GeneFxSM Colon?
Colon is a microarray-based gene signature developed for stage II colon cancer patients from FFPE tissue. GeneFxSM
Colon is performed on a small amount of tissue, removed during surgery or a biopsy. The signature identifies patients at higher risk of recurrence within 5 years following initial surgery.